CETTA, ILARIA
 Distribuzione geografica
Continente #
NA - Nord America 85
EU - Europa 43
AS - Asia 16
AF - Africa 1
Totale 145
Nazione #
US - Stati Uniti d'America 84
IT - Italia 24
SE - Svezia 13
CN - Cina 5
IN - India 4
TR - Turchia 3
FI - Finlandia 2
HK - Hong Kong 2
IE - Irlanda 2
JP - Giappone 2
CA - Canada 1
DE - Germania 1
GH - Ghana 1
UA - Ucraina 1
Totale 145
Città #
New York 24
Milan 13
Ashburn 11
Ankara 3
Coimbatore 3
Florence 3
Lawrence 3
Perugia 3
Princeton 3
Shanghai 3
Washington 3
Dublin 2
Helsinki 2
Hong Kong 2
San Cipriano d'Aversa 2
Tokyo 2
Falls Church 1
Laurel 1
Los Angeles 1
Newark 1
Pune 1
Rieti 1
Rome 1
Seattle 1
Totale 90
Nome #
Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report 27
Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience 23
Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study 21
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study 20
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN) 18
Stress in paediatric migraine: a trigger factor? 14
Imaging the brain and vascular reactions to headache treatments: a systematic review 13
Stress related to COVID-19 pandemic as a trigger for disease activity in multiple sclerosis: a case report 13
Tracking the evolution of non-headache symptoms through the migraine attack 12
Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 10
Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study) (The Journal of Headache and Pain, (2022), 23, 1, (46), 10.1186/s10194-022-01396-x) 7
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study 3
Totale 181
Categoria #
all - tutte 1.394
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.394


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 1 0 0 0 0 0 0
2021/20228 0 1 1 0 0 0 0 0 0 0 5 1
2022/202352 8 6 7 0 3 3 2 2 3 0 3 15
2023/2024120 7 16 16 14 13 27 3 16 4 4 0 0
Totale 181